mulberry wallet sale David Lillicrap
Selected Administrative Appointments World Health Organization/World Federation of Hemophilia Working Group on Genetic Diagnosis in the Hemophilias, 1991 1992
International Society for Thrombosis and Haemostasis Scientific Standardisation Committee on VWD, 1998 Present
Member, Medical and Scientific Advisory Council (MASAC) for the National Hemophilia Foundation (USA), 2002 Present
Member, Gene Therapy Working Group of the National Hemophilia Foundation (USA), 2000 Present
International Society for Thrombosis and Haemostasis Council of the Scientific Standardisation Committee, 2002 Present
Research Interests All of the research being undertaken by this group relates to molecular aspects of the hemostatic (coagulation) system. In the normal physiological state, a delicate balance is preserved between pro and anti coagulant factors that contributes to the maintenance of the normal circulation. When this balance is disrupted, bleeding or thrombosis occurs.
This research program utilizes the potential of molecular genetics and molecular biology to address a variety questions relating to pathological hemostasis. The studies range from an investigation of the mechanisms regulating production of the adhesive hemostatic protein, von Willebrand Factor, to the development of strategies for gene therapy for the inherited bleeding disease, hemophilia.
Swystun LL, Lillicrap D. How much do we really know about von Willebrand disease? Curr Opin Hematol. 2016 Jul 15. [Epub ahead of print]
Shima M, Lillicrap D, Kruse Jarres R. 2016 Jul;22 Suppl 5:36 41. doi: 0.1111/hae.13005.
Lai JD, Moorehead PC, Sponagle K, Steinitz KN, Reipert BM, Hough C, Lillicrap D. Concurrent influenza vaccination reduces anti FVIII antibody responses in murine hemophilia A. Blood. 2016;127(26):3439 49.
Nichols TC, Hough C, Agers H, Ezban M, Lillicrap D. Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies. J Thromb Haemost. 2016;14(5):894 905.
Swystun LL, Lillicrap D. Gene Therapy for Coagulation Disorders. Circ Res. 2016 Apr 29;118(9):1443 52.
Othman M, Kaur H, Favaloro EJ, Lillicrap D, Di Paola J, Harrison P, Gresele P; Subcommittees on von Willebrand Disease and Platelet Physiology. Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH. J Thromb Haemost. 2016 Feb;14(2):411 4.
Albanez S, Ogiwara K, Michels A, Hopman W, Grabell J,
James P, Lillicrap D. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms. J Thromb Haemost. 2016 May;14(5):953 63.
Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, Hoots WK, Manco Johnson MJ, Gruppo RA, Boggio LN, Montgomery KT, Goodeve AC, James PD, Lillicrap D, Peake IR, Montgomery RR. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood. 2016 May 19;127(20):2481 8.
Krishnamoorthy S, Liu T, Drager D, Patarroyo White S, Chhabra ES, Peters R, Josephson N, Lillicrap D, Blumberg RS, Pierce GF, Jiang H. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. Cell Immunol. 2016 Mar;301:30 9.
Georgescu MT, Lai JD, Hough C, Lillicrap D. War and peace: Factor VIII and the adaptive immune response. Cell Immunol. 2016;301:2 7.
Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high titer factor VIII inhibitor. J Pediatr Hematol Oncol. 37: e220 222, 2015